These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 6459558)

  • 1. Sequential hormone-chemotherapy (MAP at high doses and CMF) in metastatic breast cancer. Preliminary results.
    Pannuti F; Di Marco AR; Rossi AP; Rocchetta G; Rubino I; Giovannini M; Fruet F
    Panminerva Med; 1981; 23(2):93-6. PubMed ID: 6459558
    [No Abstract]   [Full Text] [Related]  

  • 2. Monochemotherapy (Adriamycin) for metastatic breast cancer in progression after sequential hormone-chemotherapy (MAP and CMF). Pilot study.
    Pannuti F; Rossi AP; Di Marco AR; Fruet F; Lelli G; Strocchi E; Rocchetta G; Piana E; Martoni A
    Panminerva Med; 1981; 23(1):25-8. PubMed ID: 7290722
    [No Abstract]   [Full Text] [Related]  

  • 3. Cyclophosphamide, methotrexate and fluorouracil (CMF) versus hormonal ablation with leuprorelin acetate as adjuvant treatment of node-positive, premenopausal breast cancer patients: preliminary results of the TABLE-study (Takeda Adjuvant Breast cancer study with Leuprorelin Acetate).
    Schmid P; Untch M; Wallwiener D; Kossé V; Bondar G; Vassiljev L; Tarutinov V; Kienle E; Lüftner D; Possinger K;
    Anticancer Res; 2002; 22(4):2325-32. PubMed ID: 12174922
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mitoxantrone, 5-fluorouracil, and high dose leucovorin (NFL) versus intravenous cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) in first-line chemotherapy for patients with metastatic breast carcinoma: a randomized phase II trial.
    Hainsworth JD; Jolivet J; Birch R; Hopkins LG; Greco FA
    Cancer; 1997 Feb; 79(4):740-8. PubMed ID: 9024712
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness of intermediate-dose methotrexate and high-dose 5-fluorouracil as sequential combination chemotherapy in refractory breast cancer and as primary therapy in metastatic adenocarcinoma of the colon.
    Tisman G; Wu SJ
    Cancer Treat Rep; 1980; 64(8-9):829-35. PubMed ID: 7448820
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Clinical evaluation of cyclophosphamide, methotrexate and 5-fluorouracil (CMF) on advanced and recurrent breast cancer. Clinical study group of CMF for breast cancer in Japan].
    Nomura Y; Tominaga T; Adachi I; Koyama H; Fukami A
    Gan To Kagaku Ryoho; 1994 Sep; 21(12):1949-56. PubMed ID: 8085846
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CCNU, melphalan, methotrexate, and prednisone (CAMP) versus cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) in the treatment of advanced breast cancer in postmenopausal women.
    Salimtschik M; Snel S; Havsteen H; Dombernowsky P; Mouridsen HT
    Cancer Treat Rep; 1980; 64(4-5):635-7. PubMed ID: 7000346
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Combined drug/hormone therapy in metastatic breast cancer with vincristine, adriamycin, cyclophosphamide and high dose medroxyprogesterone acetate--VAC-MAP. Preliminary results of a phase II study of the German Cancer Society's Internal Medicine Oncology Task Force].
    Wander HE; Nagel GA; Blossey HC; Kordilla F; Stamm S; Matthressen W; Weiss J
    Onkologie; 1982 Aug; 5 Suppl():8-12. PubMed ID: 6752794
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Primary chemotherapy of metastatic breast carcinoma with bendamustine hydrochloride, methotrexate and fluorouracil versus cyclophosphamide, methotrexate and fluorouracil].
    Ruffert K
    Zentralbl Chir; 1998; 123 Suppl 5():156-8. PubMed ID: 10063603
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Concurrent cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy and radiotherapy for breast carcinoma: a well tolerated adjuvant regimen.
    Isaac N; Panzarella T; Lau A; Mayers C; Kirkbride P; Tannock IF; Vallis KA
    Cancer; 2002 Aug; 95(4):696-703. PubMed ID: 12209711
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Natural history of more than 20 years of node-positive primary breast carcinoma treated with cyclophosphamide, methotrexate, and fluorouracil-based adjuvant chemotherapy: a study by the Cancer and Leukemia Group B.
    Weiss RB; Woolf SH; Demakos E; Holland JF; Berry DA; Falkson G; Cirrincione CT; Robbins A; Bothun S; Henderson IC; Norton L;
    J Clin Oncol; 2003 May; 21(9):1825-35. PubMed ID: 12721260
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjuvant combination chemotherapy for operable breast cancer. Trials in progress at the Istituto Nazionale Tumori of Milan.
    Bonadonna G; Rossi A; Tancini G; Bajetta E; Marchini S; Brambilla C; Tesoro Tess JD; Valagussa P; Banfi A; Veronesi U
    Cancer Treat Rep; 1981; 65 Suppl 1():61-5. PubMed ID: 7034930
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Medroxyprogesterone acetate (MAP) in high doses in the treatment of breast cancer in advanced stages].
    Pannuti F; Di Marco AR; Martoni A; Fruet F; Strocchi E; Burroni P; Marraro D
    Minerva Ginecol; 1982 Nov; 34(11):977-9. PubMed ID: 7155427
    [No Abstract]   [Full Text] [Related]  

  • 14. Adjuvant therapy for operable breast cancer with medroxyprogesterone acetate alone in postmenopausal patients or in combination with CMF in premenopausal patients.
    Pannuti F; Martoni A; Cilenti G; Camaggi CM; Fruet F
    Eur J Cancer Clin Oncol; 1988 Mar; 24(3):423-9. PubMed ID: 2968262
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized trial comparing cyclophosphamide, epirubicin, and fluorouracil with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer: update of National Cancer Institute of Canada Clinical Trials Group Trial MA5.
    Levine MN; Pritchard KI; Bramwell VH; Shepherd LE; Tu D; Paul N;
    J Clin Oncol; 2005 Aug; 23(22):5166-70. PubMed ID: 16051958
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized, controlled trial of cyclophosphamide, methotrexate, and fluorouracil versus cyclophosphamide, doxorubicin, and fluorouracil with and without tamoxifen for high-risk, node-negative breast cancer: treatment results of Intergroup Protocol INT-0102.
    Hutchins LF; Green SJ; Ravdin PM; Lew D; Martino S; Abeloff M; Lyss AP; Allred C; Rivkin SE; Osborne CK
    J Clin Oncol; 2005 Nov; 23(33):8313-21. PubMed ID: 16293862
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The potential risk of neoadjuvant chemotherapy in breast cancer patients--results from a prospective randomized trial of the Austrian Breast and Colorectal Cancer Study Group (ABCSG-07).
    Taucher S; Steger GG; Jakesz R; Tausch C; Wette V; Schippinger W; Kwasny W; Reiner G; Greil R; Dubsky P; Poestlberger S; Tschmelitsch J; Samonigg H; Gnant M;
    Breast Cancer Res Treat; 2008 Nov; 112(2):309-16. PubMed ID: 18080748
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Medroxyprogesterone acetate as glucocorticoid in combination with aminoglutethimide in the treatment of metastatic breast cancer].
    Blossey HC; Wander HE; Nagel GA; Köbberling J; Kleeberg U
    Onkologie; 1982 Aug; 5 Suppl():34-41. PubMed ID: 6290955
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hormone therapy in advanced breast cancer: high dose medroxyprogesterone acetate (MAP) vs tamoxifen (TMX). Preliminary results.
    Pannuti F; Martoni A; Fruet F; Strocchi E; Di Marco AR
    Eur J Cancer (1965); 1980; Suppl 1():93-8. PubMed ID: 6459237
    [No Abstract]   [Full Text] [Related]  

  • 20. [Chemotherapy of advanced breast cancer--actual results ].
    Matthes ML; Lenk H; Gürtler R; Tanneberger S
    Arch Geschwulstforsch; 1982 May; 52(3):241-6. PubMed ID: 6812538
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.